ClinicalTrials.gg
Active, not recruitingNCT05538130Updated Sep 1, 2026

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

A Phase 1 interventional study of PF-07799544 and PF-07799933 in Melanoma, Glioma and Thyroid Cancer, sponsored by Pfizer. Active, not recruiting at 66 sites in 7 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Primary conditionNeoplasms(registry's first term: Melanoma)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Melanoma, so we do not take that as its main condition. It is compared within Neoplasms.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
148
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Study summary

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b).

Phase 1a is no longer open for enrollment. In Phase1b (noted as "this study"), we are seeking participants who have:

  • a solid tumor which is metastatic or recurrent (excluding colorectal cancer)
  • tumor with the mutation (abnormal gene) called "BRAF V600"
  • received required prior treatment for cancer per cohort assigned.

All participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day.

Participants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.

02

Conditions studied

  • Melanoma
  • Glioma
  • Thyroid Cancer
  • Non-Small Cell Lung Cancer
  • Malignant Neoplasms
  • Brain Neoplasms
  • Advanced or Metastatic Solid Tumors
  • HGG
  • LGG
  • Low Grade Glioma
  • High Grade Glioma
  • Differentiated Thyroid Cancer
  • NSCLC (Non-small Cell Lung Cancer)

Browse trials for

Keywords

  • solid tumors
  • BRAF
  • advanced solid tumors
  • B-Raf
  • MAPK
  • neoplasms
  • BRAF V600
03

In context

Neoplasms Many cancers

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 148 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.

Compared within Neoplasms: the study is open to many cancers; the registry's first condition term is Melanoma. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Phase 1b Inclusion Criteria:

  • Diagnosis of advanced/ solid tumor (excluding colorectal cancer)
  • by version 1.1
  • Evidence of a BRAF V600 mutation
  • Prior therapy per tumor cohort
  • Adequate organ function per protocol

Phase 1b Exclusion Criteria:

  • Other active within 3 years
  • Presence of
  • History or current evidence of retinal vein occlusion (RVO) or history of retinal degenerative disease
  • Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
  • Active gastrointestinal disease as defined per protocol
  • History of interstitial lung disease as defined per protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Phase 1a Monotherapy Dose Escalation

    Participants will receive PF-07799544

    Drug: PF-07799544

  • Experimental
    Phase 1b Combination Dose Escalation

    Participants will receive PF-07799544 and PF-07799933

    Drug: PF-07799544 · Drug: PF-07799933

  • Experimental
    Phase 1b Combination Dose Expansion

    Participants will receive PF-07799544 and PF-07799933

    Drug: PF-07799544 · Drug: PF-07799933

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with dose limiting toxicities (DLTs)

    DLTs will be evaluated during the first cycle (21 days) as a single agent (phase 1a monotherapy) or in combination with other agents (phase 1b dose escalation)

    Time frame: Cycle 1 (21 days)

  2. Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with treatment-emergent adverse events (AEs)

    AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy

    Time frame: Baseline to 28 days after last dose of study medication

  3. Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in laboratory abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity, and timing.

    Time frame: Baseline to 28 days after last dose of study treatment

  4. Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in vital sign abnormalities

    Vital sign abnormalities as characterized by type, frequency, severity, and timing.

    Time frame: Baseline to 28 days after last dose of study treatment

  5. Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in physical exam abnormalities

    Physical exam abnormalities as as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Baseline to 28 days after last dose of study treatment

  6. Phase 1b Dose Expansion: Overall response rate (ORR)

    Response will be evaluated via radiographical tumor assessments by RECIST v1.1 for solid tumors or RANO for primary brain tumors

    Time frame: Baseline to 2 years

Secondary outcomes

  1. Phase 1a monotherapy and Phase 1b combination dose escalation: ORR

    ORR as assessed using the RECIST version 1.1.

    Time frame: Baseline to 2 years

  2. Phase 1b Dose Expansion: Number of participants with treatment-emergent adverse events (AEs)

    AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy

    Time frame: Baseline to 2 years

  3. Phase 1b Dose Expansion: Number of participants with clinically significant change from baseline in vital sign abnormalities

    Vital sign abnormalities as characterized by type, frequency, severity, and timing.

    Time frame: Baseline to 2 years

  4. Phase 1b Dose Expansion: Number of participants with clinically significant change from baseline in laboratory abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity, and timing.

    Time frame: Baseline to 2 years

  5. Phase 1b Dose Expansion: Duration of Response (Overall and in CNS)

    Response will be evaluated via radiographical tumor assessments by RECIST v1.1 for solid tumors or RANO for primary brain tumors

    Time frame: Baseline to 2 years

  6. Phase 1b Dose Expansion: Intracranial response

    Intracranial response by RECIST version 1.1 (for brain metastases)

    Time frame: Baseline to 2 years

  7. Phase 1b Dose Expansion: Progression Free Survival (PFS)

    Response will be evaluated via radiographical tumor assessments by RECIST v1.1 for solid tumors or RANO for primary brain tumors

    Time frame: Baseline to 2 years

  8. PK Parameters: Maximum Observed Concentration (Cmax)

    Single dose and multiple dose PK will be calculated as data permits

    Time frame: Baseline to 2 years

  9. PK Parameters: Maximum Plasma Concentration (Tmax)

    Single dose and multiple dose PK will be calculated as data permits

    Time frame: Baseline to 2 years

  10. PK Parameters: Area Under Curve (AUC)

    Single dose and multiple dose PK will be calculated as data permits

    Time frame: Baseline to 2 years

  11. PK Parameters: terminal elimination half-life (t½)

    Singe dose and multiple dose PK will be calculated as data permits

    Time frame: Baseline to 2 years

  12. PK Parameters: Apparent Oral Clearance (CL/F)

    Singe dose and multiple dose PK will be calculated as data permits

    Time frame: Baseline to 2 years

  13. PK Parameters: Apparent Volume of Distribution (Vz/F)

    Singe dose and multiple dose PK will be calculated as data permits

    Time frame: Baseline to 2 years

07

Study locations

66 sites
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Aug 2027, 57 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 57 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2022
First posted
Sep 13, 2022
StartActual
Nov 30, 2022
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05538130
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 13, 2022
Start date
Nov 30, 2022
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Polfurmetinib

Start the discussion